Venetoclax (ABT-199)
别名: GDC-0199
目录号:S8048 Purity: 99.97%
Venetoclax (ABT-199, GDC-0199)是一种Bcl-2选择性抑制剂,无细胞试验中Ki为<0.01 nM,比作用于Bcl-xL和Bcl-w选择性高4800倍以上,对Mcl-1没有抑制活性。有研究证明 Venetoclax 在三阴性乳腺癌 MDA-MB-231 细胞中诱导细胞生长抑制,凋亡,细胞周期停滞和自噬。Phase 3。
CAS: 1257044-40-8
客户使用Selleck的Venetoclax (ABT-199)发表文献563篇
- Nature, 2024
- Nat Immunol, 2024 10.1038/s41590-024-01952-4
- J Hematol Oncol, 2024 17(1):85
- Cancer Cell, 2022 40(3):301-317.e12
- Cancer Cell, 2022 40(2):168-184.e13
- Cancer Discov, 2022 12(2):432-449
- Blood, 2022 blood.2021014304
- Blood, 2022 blood.2022016090
- Nature, 2021 10.1038/s41586-021-04244-1
- J Hematol Oncol, 2021 14(1):70
- Cancer Discov, 2021 candisc.0551.2021
- Signal Transduct Target Ther, 2020 26;5:17
- Signal Transduct Target Ther, 2020 26;5(1):17
- Nat Genet, 2020 52(4):408-417
- J Hematol Oncol, 2020 13(1):95
- Cancer Discov, 2020 CD-20-0756
- Cell, 2019 36(2):179-193
- Cell, 2019 178(2):302-315.e23
- Cancer Cell, 2019 10.1016/j.ccell.2019.08.005
- Cancer Cell, 2019 35(5):752-766
- Cancer Cell, 2019 36(2):179-193
- Cell Metab, 2019 29(5):1217-1231
- J Hematol Oncol, 2019 12(1):73
- Cancer Discov, 2019 9(7):890-909
- Blood, 2019 134(21):1821-1831
- Cancer Cell, 2018 34(6):982-995
- Nat Mater, 2018 17(4):361-368
- Cancer Discov, 2018 8(12):1566-1581
- Cancer Discov, 2018 8(12):1598-1613
- Signal Transduct Target Ther, 2017 2:17012
- Cell Discov, 2017 3:16048
- Nat Cell Biol, 2017 19(10):1226-1236
- Nature, 2016 538(7626):477-482
- Nat Microbiol, 2016 1:15034
- Blood, 2016 128(14):1834-1844
- J Hematol Oncol, 2015 8:121
- Blood, 2015 126(11):1346-56
- Blood, 2015 125(2):407-10
- Blood, 2015 24;126(13):1565-74
- Nat Commun, 2024 15(1):1821
- Cell Death Differ, 2024 10.1038/s41418-024-01418-y
- Cell Death Differ, 2024 10.1038/s41418-024-01417-z
- Theranostics, 2024 14(7):2656-2674
- Leukemia, 2024 38(1):136-148
- Leukemia, 2024 10.1038/s41375-024-02222-w
- Cancer Res, 2024 10.1158/0008-5472.CAN-23-3574
- Proc Natl Acad Sci U S A, 2024 121(44):e2405085121
- Cancer Lett, 2024 588:216797
- Cell Death Dis, 2024 15(9):677
- Cell Death Dis, 2024 15(2):131
- Cell Death Dis, 2024 15(5):323
- Br J Cancer, 2024 10.1038/s41416-024-02740-5
- Cell Rep, 2024 43(10):114784
- Blood Adv, 2024 bloodadvances.2024013423
- J Transl Med, 2024 22(1):867
- Apoptosis, 2024 10.1007/s10495-024-02014-8
- Cell Death Discov, 2024 10(1):417
- Cell Death Discov, 2024 10(1):35
- PLoS Pathog, 2024 20(8):e1012291
- Hemasphere, 2024 8(12):e70036
- Br J Haematol, 2024 10.1111/bjh.19658
- Arch Toxicol, 2024
- Cells, 2024 13(6)528
- Biochem Pharmacol, 2024 S0006-2952(24)00048-0
- iScience, 2024 27(1):108503
- Int J Mol Sci, 2024 25(2)766
- Int J Mol Sci, 2024 25(6)3453
- Oncotarget, 2024 15:220-231
- Cancers (Basel), 2024 16(8)1448
- Eur J Pharmacol, 2024 968:176418
- Sci Rep, 2024 14(1):4975
- Life Sci Alliance, 2024 7(4)e202302353
- Dis Model Mech, 2024 17(5)dmm050631
- Toxicol Appl Pharmacol, 2024 492:117103
- In Vivo, 2024 38(4):1740-1749
- bioRxiv, 2024 2024.01.27.577579
- Res Sq, 2024 rs.3.rs-5307127
- bioRxiv, 2024 2024.02.27.582353
- bioRxiv, 2024 2024.04.12.589110
- J Clin Invest, 2023 133(3)e165694
- J Clin Invest, 2023 133(16)e167651
- Cell Rep Med, 2023 4(9):101178
- Cell Rep Med, 2023 4(11):101290
- Leukemia, 2023 37(8):1649-1659
- Leukemia, 2023 37(8):1611-1625
- J Adv Res, 2023 10.1016/j.jare.2023.10.010
- Haematologica, 2023 108(10):2626-2638
- Cell Death Dis, 2023 10.1038/s41419-023-06233-w
- Cell Death Dis, 2023 14(7):441
- Clin Cancer Res, 2023 29(16):3151-3161
- Cell Rep, 2023 42(10):113176
- Cell Rep, 2023 42(4):112324
- Cell Rep, 2023 42(2):112058
- Br J Cancer, 2023 10.1038/s41416-023-02430-8
- Front Immunol, 2023 14:1078958
- Cell Death Discov, 2023 9(1):1
- Cells, 2023 12(15)1924
- Cells, 2023 12(5)800
- Cells, 2023 10.3390/cells12182247
- Commun Biol, 2023 6(1):1271
- iScience, 2023 26(8):107369
- Biochem Pharmacol, 2023 216:115759
- iScience, 2023 26(6):106962
- Int J Mol Sci, 2023 10.3390/ijms242115571
- Cancers (Basel), 2023 15(3)745
- Int J Oncol, 2023 62(5)64
- Cancers (Basel), 2023 10.3390/cancers15194799
- Cancers -Basel), 2023 15(18)4481
- Eur J Pharmacol, 2023 956:175957
- Biomedicines, 2023 11(6)1666
- Front Oncol, 2023 13:1218989
- Front Oncol, 2023 13:1196005
- Life Sci Alliance, 2023 6(11)e202301955
- NPJ Syst Biol Appl, 2023 9(1):23
- PLoS One, 2023 18(1):e0280507
- Sci Adv, 2023 9(15):eadf8522
- Res Sq, 2023 rs.3.rs-2570204
- bioRxiv, 2023 2023.08.01.551480
- Nat Commun, 2022 13(1):5676
- Nat Commun, 2022 13(1):6226
- Nat Commun, 2022 13(1):1199
- Nat Commun, 2022 13(1):1318
- Nat Chem Biol, 2022 10.1038/s41589-022-00996-7
- Theranostics, 2022 12(5):2427-2444
- Clin Cancer Res, 2022 28-20:4444-4455
- EMBO J, 2022 41(16):e110476
- J Exp Clin Cancer Res, 2022 41(1):340
- Cancer Res, 2022 canres.0218.2021
- EMBO Mol Med, 2022 e14990
- Haematologica, 2022 10.3324/haematol.2022.280879
- Haematologica, 2022 10.3324/haematol.2022.281538
- Haematologica, 2022 107(8):1796-1814
- Cell Death Dis, 2022 13(11):979
- Cell Death Dis, 2022 13(4):379
- Cell Rep, 2022 40(5):111153
- Cell Rep, 2022 41(1):111445
- Cell Rep, 2022 38(1):110197
- Oncogene, 2022 41(28):3655-3663
- Oncogene, 2022 41(40):4560-4572
- NPJ Precis Oncol, 2022 6(1):73
- Antiviral Res, 2022 207:105417
- Blood Adv, 2022 bloodadvances.2021006348
- Breast Cancer Res, 2022 24(1):41
- J Transl Med, 2022 20(1):299
- Front Immunol, 2022 13:832263
- Cell Death Discov, 2022 8(1):11
- Antioxidants (Basel), 2022 11(3)461
- Mol Oncol, 2022 16(15):2823-2842
- Hemasphere, 2022 6(8):e752.
- Mol Oncol, 2022 16(20):3735-3753
- iScience, 2022 25(11):105458
- Biochem Pharmacol, 2022 205:115283
- Int J Mol Sci, 2022 23(19)11393
- Front Pharmacol, 2022 13:933112
- Int Immunopharmacol, 2022 104:108497
- Int J Mol Sci, 2022 23(13)6956
- Int J Mol Sci, 2022 23(12)6568
- Int J Mol Sci, 2022 23(11)6305
- Int J Mol Sci, 2022 23(22)13751
- Front Cell Dev Biol, 2022 10:768579
- Front Cell Dev Biol, 2022 10:935023
- Biomolecules, 2022 12(7)904
- Oncotarget, 2022 13:319-330
- Am J Cancer Res, 2022 12(3):1102-1115
- J Cell Mol Med, 2022 26(10):3068-3073
- Cancers (Basel), 2022 14(23)5943
- Cancers (Basel), 2022 14(21)5241
- Cancers (Basel), 2022 15(1)296
- Cancers (Basel), 2022 14(22)5602
- Cancers (Basel), 2022 14(4)983
- Cancers (Basel), 2022 14(6)1489
- Transl Oncol, 2022 18:101354
- Neoplasia, 2022 24(2):109-119
- FASEB J, 2022 36(10):e22514
- Front Oncol, 2022 12:1048741
- Biomedicines, 2022 10(3)638
- Front Oncol, 2022 12:835290
- Ann Transl Med, 2022 10(8):490
- Pharmaceuticals (Basel), 2022 15(1)91
- Heliyon, 2022 8(10):e11004
- Exp Cell Res, 2022 414(2):113105
- J Biochem Mol Toxicol, 2022 e23267.
- ProQuest, 2022 30540633
- Discov Oncol, 2022 13(1):55
- BMC Genom Data, 2022 23(1):30
- Cell Death Differ, 2021 10.1038/s41418-021-00816-w
- Leukemia, 2021 10.1038/s41375-021-01347-6
- Blood Cancer Discov, 2021 2(1):70-91
- Haematologica, 2021 10.3324/haematol.2020.272609
- Haematologica, 2021 10.3324/haematol.2021.278743
- Cell Death Dis, 2021 12(4):406
- Cell Death Dis, 2021 12(6):577
- Cell Death Dis, 2021 12(8):784
- Cell Rep, 2021 34(11):108870
- Br J Cancer, 2021 10.1038/s41416-021-01441-7
- Cell Chem Biol, 2021 S2451-9456(21)00400-1
- Elife, 2021 10e63104
- Blood Adv, 2021 5(10):2467-2480
- Blood Adv, 2021 5(3):700-710
- Blood Adv, 2021 5(23):5060-5071
- Antioxidants (Basel), 2021 10(6)956
- Mol Oncol, 2021 10.1002/1878-0261.13153
- Int J Cancer, 2021 10.1002/ijc.33865
- Biochem Pharmacol, 2021 190:114660
- Cancer Sci, 2021 112(9):3645-3654
- Mol Cancer Ther, 2021 20(12):2483-2494
- Int J Mol Sci, 2021 22(8)3811
- Int J Mol Sci, 2021 22(19)10761
- Front Cell Dev Biol, 2021 9:765973
- Mol Cancer Res, 2021 19(6):1026-1039
- Cancers (Basel), 2021 14(1)181
- Cancers (Basel), 2021 13(2)E361
- Cancers (Basel), 2021 14(1)14
- Cancers (Basel), 2021 13(23)5966
- Cancers (Basel), 2021 13(14)3585
- Front Mol Biosci, 2021 8:645846
- Transl Oncol, 2021 14(5):101048
- Neoplasia, 2021 23(12):1183-1191
- Front Oncol, 2021 11:692497
- Front Oncol, 2021 11:618908
- Front Oncol, 2021 11:696532
- Ann Transl Med, 2021 9(20):1575
- Sci Rep, 2021 11(1):21230
- PLoS Comput Biol, 2021 17(2):e1008630
- Int J Biochem Cell Biol, 2021 137:106028
- J Cancer, 2021 12(22):6727-6739
- Biomed Res Int, 2021 2021:6615502
- Neuroscience, 2021 S0306-4522(21)00070-1
- Biochem Biophys Res Commun, 2021 562:55-61
- Exp Hematol, 2021 S0301-472X(21)00424-0
- Biol Pharm Bull, 2021 10.1248/bpb.b21-00531
- Anticancer Res, 2021 41(9):4239-4248
- Nat Commun, 2020 11(1):752
- Nat Commun, 2020 26;11(1):2641
- Nat Commun, 2020 11(1):259
- Mol Cell, 2020 7;S1097-2765(20)30269-0
- Cell Death Differ, 2020 10.1038/s41418-020-0496-1
- Genome Med, 2020 18;12(1):17
- J Exp Clin Cancer Res, 2020 39(1):228
- Cancer Res, 2020 10.1158/0008-5472.CAN-19-1784
- Haematologica, 2020 10.3324/haematol.2019.227215
- Haematologica, 2020 105(11):2584-2591
- Haematologica, 2020 12;haematol.2019.233445
- Haematologica, 2020 15 pii: haematol 2019 244020
- Cancer Lett, 2020 S0304-3835(20)30635-2
- Cancer Lett, 2020 482:19-32
- Cell Death Dis, 2020 5;11(5):316
- Cell Death Dis, 2020 11(10):884
- Cell Death Dis, 2020 11(2):156
- Cell Death Dis, 2020 11(10):875
- Cell Death Dis, 2020 11(11):956
- Cell Death Dis, 2020 11(8):634
- Cell Death Dis, 2020 11(8):701
- Br J Cancer, 2020 122(10):1544-1551
- Mol Ther Nucleic Acids, 2020 1;20:801-811
- Eur J Cancer, 2020 126:93-103
- Acta Pharmacol Sin, 2020 10.1038/s41401-020-00504-4
- JCI Insight, 2020 5 pii: 132963
- Elife, 2020 2;9:e54954
- Blood Adv, 2020 4(17):4217-4231
- Blood Adv, 2020 4(17):4124-4135
- Blood Adv, 2020 4(3):525-529
- Blood Adv, 2020 4(5):819-829
- Blood Adv, 2020 4(20):5062-5077
- Blood Adv, 2020 4(20):5226-5231
- Breast Cancer Res, 2020 22(1):130
- J Med Chem, 2020 63(22):13733-13744
- Int J Radiat Oncol Biol Phys, 2020 15;106(4):867-877
- Mol Oncol, 2020
- J Cell Mol Med, 2020 24(2):1650-1657
- Am J Cancer Res, 2020 10(10):3406-3414
- Cancers (Basel), 2020 12(9)E2400
- Cancers (Basel), 2020 12(6):1694
- Cancers (Basel), 2020 12(7):1883
- Aging (Albany NY), 2020 12(14):14174-14188
- Mol Cancer Res, 2020 molcanres.0586.2020
- Cancers (Basel), 2020 12(8):E2182
- Cancers (Basel), 2020 12(2)
- Am J Physiol Lung Cell Mol Physiol, 2020 10.1152/ajplung.00046.2020
- Eur J Pharm Sci, 2020 142:105105
- Allergy Asthma Immunol Res, 2020 12(4):608-625
- Cancer Med, 2020 10.1002/cam4.3665
- PLoS Negl Trop Dis, 2020 14(3):e0008150
- BMC Cancer, 2020 20(1):984
- PLoS One, 2020 15(7):e0234103
- Platelets, 2020 10.1080/09537104.2020.1724276
- Eur J Haematol, 2020 10.1111/ejh.13492
- Oncol Res, 2020 10.3727/096504020X15825405463920
- Biochem Biophys Res Commun, 2020 525(3):549-556
- Leuk Lymphoma, 2020 1-12
- Exp Hematol, 2020 81:32-41
- In Vivo, 2020 34(2):511-516
- EJHaem, 2020 1(1):122-132
- J Clin Invest, 2019 130189
- Nat Chem Biol, 2019 15(3):232-240
- Biomaterials, 2019 192:429-439
- Blood Cancer J, 2019 9(12):87
- Blood Cancer J, 2019 9(2):4
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-0775
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-0713
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-0832
- Leukemia, 2019 10.1038/s41375-019-0491-z
- Leukemia, 2019 10.1038/s41375-019-0569-7
- Cancer Res, 2019 79(19):4855-4868
- Cancer Res, 2019 10.1158/0008-5472
- EMBO Mol Med, 2019 11(10):e10769
- Haematologica, 2019 10.3324/haematol.2018.206631
- Haematologica, 2019 10.3324/haematol.2019.229997
- Haematologica, 2019 haematol.2019.220525
- Cell Death Dis, 2019 10(7):521
- Cell Death Dis, 2019 10(5):342
- Cell Death Dis, 2019 10(6):421
- Cell Death Dis, 2019 10(12):917
- Cell Death Dis, 2019 10(12):912
- Mol Ther Nucleic Acids, 2019 18:476-484
- Br J Cancer, 2019 120(12):1137-1146
- Oncogene, 2019 38(1):47-59
- Blood Adv, 2019 3(20):2920-2933
- Front Immunol, 2019 10:2455
- Front Immunol, 2019 10:2972
- Front Immunol, 2019 10:2286
- Cell Death Discov, 2019 5:117
- Cell Oncol (Dordr), 2019 42(3):287-301
- Mol Cancer Ther, 2019 10.1158/1535-7163.MCT-18-1080
- J Cell Physiol, 2019 234(8):14040-14049
- Int J Mol Sci, 2019 20(23)
- Target Oncol, 2019 14(3):351-364
- Oncotarget, 2019 10(58):6219-6233
- Cancers (Basel), 2019 11(11)
- Cancers (Basel), 2019 11(10)
- Cancers (Basel), 2019 11(6)
- Sci Rep, 2019 9(1):7193
- Sci Rep, 2019 6:27696
- Sci Rep, 2019 9(1):1265
- Oncol Rep, 2019 10.3892/or.2019.7282
- Oncol Rep, 2019 42(6):2416-2425
- Mol Pharmacol, 2019 96(4):419-429
- Curr Drug Targets, 2019 20(4):453-464
- Eur J Haematol, 2019 10.1111/ejh.13279
- Prostate, 2019 79(11):1347-1359
- Leuk Res, 2019 78:3-11
- Leuk Lymphoma, 2019 60(4):1043-1052
- Anticancer Drugs, 2019 30(2):138-148
- Nat Commun, 2018 9(1):727
- Nat Commun, 2018 9(1):3513
- Nat Commun, 2018 9(1):215
- Nat Commun, 2018 9(1):4116
- J Clin Invest, 2018 128(12):5517-5530
- Neuro Oncol, 2018 20(2):203-214
- J Exp Med, 2018 215(12):3094-3114
- J Allergy Clin Immunol, 2018 142(5):1647-1650.e3
- Autophagy, 2018 14(5):845-861
- Clin Cancer Res, 2018 24(22):5658-5672
- Clin Cancer Res, 2018 10.1158/1078-0432.CCR-18-1548
- Clin Cancer Res, 2018 24(16):3967-3980
- Cancer Res, 2018 78(8):2000-2013
- Cancer Res, 2018 78(6):1471-1483
- Proc Natl Acad Sci U S A, 2018 115(11):E2594-E2603
- Proc Natl Acad Sci U S A, 2018 115(47):12034-12039
- Cancer Immunol Res, 2018 6(10):1150-1160
- Haematologica, 2018 103(7):1218-1228
- Haematologica, 2018 10.3324/haematol.2018.204958
- Cell Death Dis, 2018 9(2):42
- Cell Death Dis, 2018 9(2):19
- Cell Death Dis, 2018 9(2):86
- Cell Death Dis, 2018 9(2):29
- Cell Death Dis, 2018 9(7):713
- Cell Death Dis, 2018 9(5):445
- Cell Rep, 2018 24(8):2155-2166
- Cell Rep, 2018 24(13):3393-3403.e5
- Cell Rep, 2018 25(9):2354-2368.e5
- Br J Cancer, 2018 118(3):388-397
- Oncogene, 2018 37(14):1830-1844
- Oncogene, 2018 37(32):4475-4488
- Oncogene, 2018 37(33):4599-4610
- Oncogene, 2018 37(39):5325-5339
- Oncogene, 2018 37(30):4122-4136
- Oncogene, 2018 37(22):2936-2952
- JCI Insight, 2018 3(19)
- EMBO Rep, 2018 19(9)
- Biomed Pharmacother, 2018 100:509-520
- Br J Pharmacol, 2018 10.1111/bph.14505
- Oncoimmunology, 2018 8(1):e1512455
- Cell Death Discov, 2018 4:107
- PLoS Pathog, 2018 14(6):e1007100
- Eur J Med Chem, 2018 159:357-380
- Br J Haematol, 2018 182(5):654-669
- Biochem Pharmacol, 2018 155:102-109
- Mar Drugs, 2018 16(12)
- Oncotarget, 2018 9(24):16701-16717
- Oncotarget, 2018 9(41):26353-26369
- Oncotarget, 2018 9(42):26834-26851
- Oncotarget, 2018 9(28):20075-20088
- Oncotarget, 2018 9(30):21166-21181
- Oncotarget, 2018 9(40):26019-26031
- Oncotarget, 2018 9(34):23505-23518
- Oncotarget, 2018 9(71):33482-33499
- Oncotarget, 2018 9(31):21820-21830
- Oncotarget, 2018 9(57):31018-31031
- Oncotarget, 2018 9(2): 2384–2394
- J Cell Mol Med, 2018 22(12):6099-6111
- Cancers (Basel), 2018 10(11)
- Aging (Albany NY), 2018 10(6):1415-1423
- Mol Neurobiol, 2018 55(1):495-505
- J Biol Chem, 2018 293(35):13750-13765
- Sci Rep, 2018 8(1):12046
- Sci Rep, 2018 8(1):15752
- Cell Physiol Biochem, 2018 48(3):1123-1138
- Cancer Med, 2018 7(7):3257-3268
- PLoS One, 2018 13(8):e0200725
- Cancer Biol Ther, 2018 19(6):465-474
- Cancer Biol Ther, 2018 19(3):239-247
- Cancer Biol Ther, 2018 19(3):239-247
- SLAS Discov, 2018 23(7):687-696
- Adv Biol Regul, 2018 67:190-211
- Nat Commun, 2017 8(1):1067
- Nat Commun, 2017 8:16078
- J Allergy Clin Immunol, 2017 140(2):418-430
- Cell Death Differ, 2017 24(5):866-877
- Clin Cancer Res, 2017 23(14):3734-3743
- Leukemia, 2017 31(11):2336-2346
- J Exp Clin Cancer Res, 2017 36(1):82
- Cancer Res, 2017 77(11):2927-2937
- Cancer Res, 2017 77(13):3513-3526
- Cancer Res, 2017 77(9):2476-2487
- Cancer Res, 2017 77(9):2512-2521
- Proc Natl Acad Sci U S A, 2017 114(2):382-387
- Proc Natl Acad Sci U S A, 2017 114(36):E7554-E7563
- Genes Dev, 2017 31(6):553-566
- Haematologica, 2017 102(7):1247-1257
- Cell Death Dis, 2017 8(10):e3133
- Cell Rep, 2017 20(4):999-1015
- Clin Immunol, 2017 181:32-42
- Eur J Cancer, 2017 83:154-165
- Oncogene, 2017 36(11):1573-1584
- Oncogene, 2017 36(23):3263-3273
- Elife, 2017 e22509
- Apoptosis, 2017 22(12):1564-1577
- Mol Cancer Ther, 2017 16(9):1979-1988
- Target Oncol, 2017 12(5):677-687
- Oncotarget, 2017 8(63):107206-107222
- Oncotarget, 2017 8(18):29558-29573
- Oncotarget, 2017 8(40):67709-67722
- Oncotarget, 2017 8(52):90013-90027
- Oncotarget, 2017 8(22):35508-35522
- Oncotarget, 2017 8(8):12953-12967
- Oncotarget, 2017 8(23):37140-37153
- Oncotarget, 2017 8(10):16259-16274
- Oncotarget, 2017 8(70):114924-114934
- Oncotarget, 2017 8(7):11042-11052
- Oncotarget, 2017 8(35):59476-59491
- Oncotarget, 2017 8(28):45088-45104
- Oncotarget, 2017 8(29):47709-47724
- Oncotarget, 2017 8(27):44295-44311
- Oncotarget, 2017 8(61):103167-103181
- Oncotarget, 2017 8(34):57047-57057
- Antimicrob Agents Chemother, 2017 61(3)
- Neoplasia, 2017 19(10):791-804
- J Biol Chem, 2017 292(36):15105-15120
- Biochimica et Biophysica Acta (BBA-- Gene Regulatory Mechanisms, 2017 -674-684
- Viruses, 2017 9(10)
- Sci Rep, 2017 7(1):18007
- Cell Cycle, 2017 16(14):1376-1383
- Cancer Biol Ther, 2017 18(8):606-615
- Leuk Res, 2017 59:124-135
- Protein Eng Des Sel, 2017 30(9):639-647
- Sci Transl Med, 2016 8(354):354ra114
- Sci Transl Med, 2016 8(339):339ra69
- Nat Commun, 2016 7:11589
- Nat Commun, 2016 7:11190
- Autophagy, 2016 12(7):1083-93
- Blood Cancer J, 2016 6:e434
- Cell Death Differ, 2016 10.1038/cdd.2016.61
- Clin Cancer Res, 2016 22(5):1138-49
- Clin Cancer Res, 2016 22(24):6099-6109
- Clin Cancer Res, 2016 22(17):4440-51
- Cancer Res, 2016 76(6):1313-9
- Proc Natl Acad Sci U S A, 2016 113(6):1624-9
- Cancer Lett, 2016 383(2):204-211
- Cell Death Dis, 2016 7(8):e2342
- Cell Death Dis, 2016 7(9):e2361
- Cell Rep, 2016 16(8):2061-2067
- Elife, 2016 10.7554/eLife.18489
- Sci Signal, 2016 9(415):ra17
- J Med Chem, 2016 59(7):3152-62
- Crit Rev Oncol Hematol, 2016 104:169-82
- Cancer Cell Int, 2016 16:27
- Mol Cancer Ther, 2016 15(10):2357-2369
- J Photochem Photobiol B, 2016 159:191-5
- J Virol, 2016 90(5):2356-71
- Oncotarget, 2016 7(35):56253-56265
- Oncotarget, 2016 7(50):83208-83222
- Oncotarget, 2016 7(46):74807-74819
- Oncotarget, 2016 7(20):29664-76
- Oncotarget, 2016 7(13):15986-6002
- Oncotarget, 2016 7(43):70000-70010
- Oncotarget, 2016 7(23):34785-99
- Oncotarget, 2016 7(45):72608-72621
- Oncotarget, 2016 7(4):4226-40
- Oncotarget, 2016 7(51):84594-84607
- Oncotarget, 2016 7(50):82013-82027
- Oncotarget, 2016 7(24):35989-36001
- Oncotarget, 2016 7(5):5507-20
- Endocrinology, 2016 157(6):2270-81
- J Biol Chem, 2016 291(51):26291-26303
- Biochim Biophys Acta, 2016 1863(4):562-71
- PLoS One, 2016 11(6):e0158617
- Biol Chem, 2016 397(7):671-8
- Exp Ther Med, 2016 11(6):2446-2454
- Clin Lymphoma Myeloma Leuk, 2016 16(11):593-606
- Exp Hematol, 2016 44(1):38-49
- Am J Transl Res, 2016 8(9):3893-3902
- J Exp Med, 2015 212(13):2189-201
- Cell Death Differ, 2015 10.1038/cdd.2015.73
- Clin Cancer Res, 2015 21(16):3705-15
- Clin Cancer Res, 2015 21(11):2558-68
- Leukemia, 2015 29(1):169-76
- Cancer Res, 2015 75(24):5318-28
- Genes Dev, 2015 29(20):2140-52
- Haematologica, 2015 100(8):e302-6
- Cell Death Dis, 2015 6:e1593
- Cell Death Dis, 2015 6:e2034
- J Med Chem, 2015 58(4):1644-68
- Apoptosis, 2015 20(7):921-9
- Mol Oncol, 2015 9(2):409-21
- Mol Oncol, 2015 9(2):409-21
- Br J Haematol, 2015 10.1111/bjh.13278
- Oncotarget, 2015 6(11):8698-708
- Oncotarget, 2015 6(31):32089-103
- Oncotarget, 2015 6(1):409-26
- Oncotarget, 2015 6(19):16912-25
- Oncotarget, 2015 6(29):27388-402
- Oncotarget, 2015 6(11):8750-9
- Oncotarget, 2015 6(25):21159-72
- Oncotarget, 2015 6(14):12668-81
- Oncotarget, 2015 6(27):23959-86
- Oncotarget, 2015 6(42):44832-48
- Oncotarget, 2015 6(38):40535-56
- Oncotarget, 2015 6(12):10399-414
- Int J Oncol, 2015 46(5):2003-10
- Sci Rep, 2015 5:17499
- Expert Opin Drug Metab Toxicol, 2015 11(9):1371-91
- PLoS One, 2015 10(3):e0120913
- PLoS One, 2015 10(9):e0138377
- PLoS One, 2015 10(11):e0143685
- Front Genet, 2015 6:207
- Cancer Biol Ther, 2015 16(12):1784-93
- Cancer Biol Ther, 2015 16(3):392-401
- Biochem Biophys Res Commun, 2015 463(4):870-5
- Cell Death Differ, 2014 21(7):1170-7
- Cell Death Differ, 2014 21(12):1877-88
- Clin Cancer Res, 2014 20(21):5446-55
- Leukemia, 2014 28(8):1657-65
- Sci Signal, 2014 7(357):ra122
- Br J Haematol, 2014 10.1111/bjh.13200
- J Biol Chem, 2014 289(23):16190-9
- Photochem Photobiol Sci, 2014 13(11):1621-7
- Leuk Lymphoma, 2014 5:1-12
- Physiol Rep, 2014 2(6)
- Genes Cancer, 2014 5(11-12):445-59
- Cell Death Dis, 2013 4:e628
- Mol Cancer Ther, 2013 12(9):1874-85
- Mol Ther, 2010 18(12):2094-103
化学信息&溶解度
分子量 | 868.44 |
分子式 | C45H50ClN7O7S |
CAS号 | 1257044-40-8 |
Smiles | CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 115.14 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 115.14 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 115.14 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 115.14 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
Corn oil
浓度:2.5mg/ml
(2.88mM)
操作示例:以 1 mL 工作液为例,取50μL50mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
10% DMSO
40% PEG 300
5%Tween80
45%ddH2O
浓度:1.8mg/ml
(2.07mM)
操作示例:以 1 mL 工作液为例,取100 μL 18mg/ml的澄清DMSO储备液加到400 μL PEG300中,混合均匀使其澄清;向上述体系中加入50 μL Tween80,混合均匀使其澄清;然后继续加入450 μL ddH2O定容至1mL。工作液请现配现用!
|
|
5%DMSO
50%PEG300
5%Tween80
40%ddH2O
浓度:2.5mg/ml
(2.88mM)
操作示例:以 1 mL 工作液为例,取50μL50mg/ml的澄清DMSO储备液加到 500μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入400μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。